NASDAQ: PYPDPolypid Ltd Stock
$0.43+0.02 (+4.88%)
Updated Jun 6, 2023
PYPD Price
$0.43
Fair Value Price
$0.86
Market Cap
$8.44M
52 Week Low
$0.33
52 Week High
$6.90
P/E
-0.21x
P/B
1.45x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$39.56M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
3.46
Operating Cash Flow
-$34M
Beta
0.91
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PYPD Overview
PolyPid LTD. is developing products based on a polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs and improve surgical results. The company's lead product candidate is D-PLEX100, to prevent sternal (bone) and abdominal (soft tissue) surgical site infections. PolyPid was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PYPD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PYPD ($0.43) is undervalued by 50.58% relative to our estimate of its Fair Value price of $0.86 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
PYPD ($0.43) is significantly undervalued by 50.58% relative to our estimate of its Fair Value price of $0.86 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
PYPD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PYPD due diligence checks available for Premium users.
Be the first to know about important PYPD news, forecast changes, insider trades & much more!
PYPD News
Valuation
PYPD fair value
Fair Value of PYPD stock based on Discounted Cash Flow (DCF)
Price
$0.43
Fair Value
$0.86
Undervalued by
50.00%
PYPD ($0.43) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PYPD ($0.43) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PYPD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PYPD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.21x
Industry
11.67x
Market
53.54x
PYPD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.45x
Industry
5.27x
PYPD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PYPD's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
PYPD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$26.0M
Liabilities
$20.1M
Debt to equity
3.46
PYPD's short-term assets ($14.19M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PYPD's short-term assets ($14.19M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PYPD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
PYPD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PYPD vs Biotech Stocks
Polypid Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.